Press Release

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

  • Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an additional $22M with milestones and other potential future payments

  • Near-term milestones for intestinal failure program buttressed by groundbreaking results of parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients

  • Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives

  • Jaguar's rare-disease pipeline is the subject of ongoing BD discussions with potential partners, targeting NDA-ready data in 12-18 months

  • Jaguar presenting January 22 at Sequire Investor Summit in Puerto Rico; click here to register for event

  • Click here to view replay of Jaguar's January 15 fireside chat during Lytham Partners Healthcare Investor Summit

Read More